Treatment of cardiac transthyretin amyloidosis: an update
Key result
Recent pharmacological agents, including tafamidis, patisiran, and inotersen, offer new therapeutic options for cardiac transthyretin amyloidosis beyond traditional transplantation.
Why the study?
ATTR is an underdiagnosed cause of morbidity and mortality with evolving therapeutic options, warranting an update following recent clinical trials along with practical management recommendations.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Advances management of cardiac ATTR amyloidosis; confirms tafamidis efficacy and extends evidence to gene silencers.
Structured PICO
P
Population
Patients with cardiac transthyretin amyloidosis (ATTR)
I
Intervention
Pharmacological agents (tafamidis, patisiran, inotersen) and transplantation
Provides an update and practical recommendations on the rapidly evolving pharmacological management of cardiac transthyretin amyloidosis.
Cite This Study
Emdin et al. (2019) conducted a review in Cardiac transthyretin amyloidosis (ATTR). Pharmacological agents (tafamidis, patisiran, inotersen) was evaluated. Recent pharmacological agents, including tafamidis, patisiran, and inotersen, offer new therapeutic options for cardiac transthyretin amyloidosis beyond traditional transplantation.